主页
市场
图表与思路
Algo
新闻
商店
经纪商
下载
经济日历
交易信号
网页端
热图
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GPCR
#1493
Structure Therapeutics Inc - American Depositary Shares
39.3
4
USD
-2.07%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
-2.07%
每月变动
-4.79%
6个月变化
+11.57%
年变化
+47.12%
前一天收盘价
40.1
7
Open
39.3
4
最低价
39.3
4
High
39.3
4
交易量
48
市场
US Stock Market
医疗保健
GPCR
展开完整图表
完整图表
Financials
概览
声明
统计
每季度
年度
利润表
资产负债表
现金流
值
2023
2024
2025
总资产
482.02 M
903.33 M
1.58 B
负债总额
29.05 M
38.49 M
67.54 M
权益总额
452.97 M
864.84 M
1.52 B
负债及股东权益总额
482.02 M
903.33 M
1.58 B
总债务
—
—
—
净债务
—
—
—
新闻
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market - TipRanks.com
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study